tert-Butyl 4-(((3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxylate

Catalog No. :
ACVMWS996
CAS No. :
1212660-14-4
Molecular Formula :
C17H30N2O6
Molecular Weight :
358.43

IUPAC Name:tert-butyl 4-(((3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxylate

tert-Butyl 4-(((3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(((3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(((3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxylate
Molecular FormulaC17H30N2O6
Molecular Weight358.43
SMILESO=C(N1CCN(C[C@@H](O2)[C@H](O)[C@]3([H])[C@@]2([H])OC(C)(C)O3)CC1)OC(C)(C)C
InChI KeyCRVNXSLBKCUKJR-XJFOESAGSA-N
Synonymtert-butyl 4-{[(3aR,5R,6S,6aR)-6-hydroxy-2,2-dimethyl-tetrahydro-2H-furo[2,3-d][1,3]dioxol-5-yl]methyl}piperazine-1-carboxylate;5-(4-tert-Butoxycarbonyl-piperazin-1-yl)-5-deoxy-1,2-isopropylidene-alpha-D-xylofuranose
CAS No.1212660-14-4

Synthetic Route by SureRoute

1. ACVMWS996 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVMWS996 route product structure diagram
    ACVMWS9961212660-14-4
Inquiry

2. ACVMWS996 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVMWS996 route product structure diagram
    ACVMWS9961212660-14-4
Inquiry

Comments (0)